Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $5.13M
• Dividend Yield: N/A
• Average Volume (3M): 2.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: 44.75%
• EPS Growth: 86.42%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 74
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -51.76
• Shares Outstanding: 3,635,945
• 10 Day Avg. Volume: 1,439,856
• 30 Day Avg. Volume: 2,915,470
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.19
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.12
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sunshine Biopharma's stock score is primarily impacted by financial performance challenges, including significant yet unprofitable revenue growth and negative cash flows. Technical analysis indicators suggest bearish momentum, further influencing the negative outlook. Valuation concerns, such as a negative P/E ratio and lack of dividend yield, also weigh on the score. The company needs to address operational inefficiencies and improve profitability to enhance its stock performance.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

How the Company Makes Money

Sunshine Biopharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by advancing its drug candidates through clinical trials and ultimately receiving regulatory approval to market these drugs. Upon approval, it can generate revenue from sales of its proprietary drugs. Additionally, Sunshine Biopharma may enter into strategic partnerships or licensing agreements with other pharmaceutical companies, providing opportunities for upfront payments, milestone payments, and royalties based on product sales. These collaborations can significantly contribute to the company's earnings by leveraging the partner's distribution networks and expertise in specific markets.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma is experiencing significant revenue growth, showcasing potential in the pharmaceuticals industry, yet continues to face challenges with profitability and cash flow management. The strong equity base and low leverage are positives, providing a buffer against operational risks. However, the company needs to focus on improving operational efficiencies and cash flow generation to enhance its financial health.

Income Statement

Sunshine Biopharma's revenue growth has been strong, showcasing a significant increase from $43,456,03 in 2022 to $32,959,492 in TTM, indicating a robust growth trajectory. However, the company continues to operate at a net loss with a negative net profit margin, suggesting ongoing profitability challenges. Both EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a healthy equity base with stockholders' equity of $25,039,312 in TTM, giving an impressive equity ratio of 83.3%. The debt-to-equity ratio is low at 0.02, indicating a conservative leverage position. However, the company needs to manage its liabilities prudently to ensure financial stability.

Cash Flow

Sunshine Biopharma's cash flow presents challenges, as indicated by negative free cash flow of $-13,906,278 in TTM and negative operating cash flow. The absence of free cash flow growth and a negative operating cash flow to net income ratio highlight liquidity pressures, potentially affecting future operations.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
24.09M	4.35M	228.43K	71.41K	21.12K
	Gross Profit
8.34M	1.70M	110.60K	45.56K	10.07K
	EBIT
-4.79M	-8.67M	-2.44M	-576.87K	-641.64K
	EBITDA
-3.82M	-26.45M	-12.09M	-2.60M	-948.38K
	Net Income Common Stockholders
-4.51M	-26.74M	-12.77M	-897.68K	-1.46M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.29M	21.83M	2.05M	989.89K	40.50K
	Total Assets
27.35M	29.24M	2.20M	1.05M	98.14K
	Total Debt
657.71K	4.27M	1.90M	1.91M	715.57K
	Net Debt
-15.63M	-17.55M	-145.17K	923.23K	675.07K
	Total Liabilities
6.14M	7.62M	1.99M	2.00M	833.53K
	Stockholders Equity
21.21M	21.63M	211.66K	-954.84K	-735.38K
Cash Flow		Free Cash Flow
-9.56M	-5.55M	-1.83M	-658.49K	-496.66K
	Operating Cash Flow
-8.78M	-5.25M	-1.83M	-657.30K	-495.80K
	Investing Cash Flow
-656.15K	-14.62M	0.00	-1.19K	-15.28K
	Financing Cash Flow
3.43M	39.47M	2.90M	1.61M	442.25K

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 1.41 is above the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.86, and below the 200-day MA of 2.82, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 39.20 is Neutral, neither overbought nor oversold. The STOCH value of 43.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
SNOA	49 Neutral	$5.46M	―	-64.83%	―	13.51%	78.93%
EVOK	46 Neutral	$4.34M	―	-240.09%	―	97.84%	82.99%
SBFM	40 Underperform	$5.13M	―	-22.97%	―	44.75%	86.42%
RDHL	38 Underperform	$2.74M	―	1155.92%	―	―	―
CPHI	35 Underperform	$4.61M	―	-61.58%	―	-35.41%	72.85%
PRFX	34 Underperform	$4.34M	―	-129.08%	―	―	9.41%

Sunshine Biopharma Corporate Events

Sunshine Biopharma Strengthens Leadership with New Executive Agreements

Sunshine Biopharma Inc. has solidified its leadership team with new employment agreements for its top executives, effective January 1, 2024. Dr. Steve N. Slilaty, CEO, Camille Sebaaly, CFO, and Dr. Abderrazzak Merzouki, COO, will receive annual salary hikes tied to inflation or a minimum increase, whichever is higher. In case of termination without cause, substantial severance packages are promised, ensuring stability and confidence in the company’s future growth strategies.